Clinical trials of sodiumglucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP1) receptor agonists have shown beneficial effects of these agents on kidney outcomes in patients with type 2 diabetes mellitus
By the 1990s, Pisano, Raufman and colleague John Eng identified a hormone-like molecule they called exendin-4
This article explains what those differences mean in real clinical practice, particularly in Dubai, where dosing availability and regulatory approval directly influence prescribing decisions
Like in our study, earlier studies have shown that the release of GLP-1 and GIP are more pronounced in the morning compared with the afternoon or evening [21]
Moon consistently logged her food, checked in for weekly weigh-ins, and watched the graph of her weight trend steadily downward
American Diabetes Association (2019) 9